Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - EU Market Recap: FTSE 100 +0.46% to 10184.35, DAX (0.53%) to 25286.24, CAC40 (0.19%) to 8330.97, STOXX 600 +0.18% to 611.56

Jan 14 ,2026

  • Synopsis:

    • European equity markets finished mostly mixed after closing little changed on Tuesday. UK FTSE 100 outperform while Germany and France ended weaker. Chemicals, basic resources and health care the best performers; tech, media and travel/leisure lag.

    • Attention centers on diplomacy and domestic politics. Meeting currently taking place at the White House between Greenland and Danish foreign ministers and US Vice President Vance and Secretary of State Rubio, amid President Trump's insistence that Greenland is vital to US national security and that anything less than American control of the territory is "unacceptable". Meanwhile, on the domestic front in France, Prime Minister Lecornu is confronting two no-confidence motions linked to the EU-Mercosur trade agreement, although their adoption is considered improbable.

    • On the monetary policy front, BoE dove Taylor expects inflation to return to 2% by mid-2026, arguing that US tariffs will have a disinflationary impact through trade diversion, as cheaper Chinese exports are redirected toward the UK and EU.

    • Amongst notable corporate updates, Bayer (BAYN.GR) targeting mid-single-digit pharma growth return by 2027 post-Xarelto cliff. Fresenius Medical Care (FME.GR) reiterated expectations for US volumes to recover but also flags additional headwinds at J.P. Morgan Healthcare Conference. In the UK, bp (BP.LN) Q4 guidance showed flat upstream production but negative realizations impact of $0.3-0.7B across segments; Pearson (PSON.LN) released its FY/Q4 trading updat with revenue growth and EBIT in line with consensus. In further corporate news, UK published the results of Allocation Round 7 (AR7) this morning. RWE (RWE.GR) is seen as a big winner from the Allocation Round 7 results; supplier Vestas (VWS.DC) is also up in reaction, while SSE (SSE.LN) secured 1 phase of the BerwickBank project, ~1.4GW, for £89.49/MWh.

    • In rumoured M&A deals, HSBC Holdings (HSBA.LN) reportedly considering selling its Singapore insurance business while BAWAG (BG.AV) is understood to be in exclusive negotiations to buy Finance Ireland in deal that values the business at estimated €250M to €300M. Also, Telefonica (TEF.SM) opened talks to acquire Vodafone Spain (ZEG.LN). Separately, the group is exploring options to repatriate profits accumulated over the past two decades that remain trapped in Venezuela.

    • Looking ahead to tomorrow's EU econ-calendar, notable releases will include, amongst others, Germany FY GDP, UK Nov industrial/manufacturing production, trade balance, construction output, Dec house price balance - RICS, monthly GDP tracker - NIESR, France Dec final CPI, Italy Nov industrial production, trade balance, Spain Dec final CPI and Eurozone Nov industrial production, trade balance.

  • Digest:

    • Sectors - STOXX Europe 600:

      • Outperformers

        • Chemicals +2.02%, Basic Resources +1.78%, Health Care +1.30%, Food & Beverage +1.24%, Utilities +1.21%, Telecom +1.12%, Autos & Parts +0.91%, Insurance +0.55%, Oil & Gas +0.50%, Construct & Mtls +0.32%, Banks +0.22%

      • Underperformers

        • Technology (1.77%), Media (1.69%), Travel & Leisure (1.23%), Ind Goods & Svcs (0.78%), Retail (0.66%), Real Estate (0.27%), Persnl & HHold Goods (0.13%), Financial Svcs (0.07%)

    • Macro:

      • Central banks:

        • Monetary policy and financial stability in the euro area -- ECB

        • The evolution of the bank's approach to resolution − speech by Dave Ramsden -- BoE

        • Minutes of the Monetary Council meeting of 16-Dec-25 -- MNB.hu

        • Press release from the meeting of the Monetary Policy Council held on 13-14-Jan-26 -- NBP.pl

      • EU:

        • Danish Armed Forces increase their presence and continue with exercises in Greenland in close cooperation with allies -- fmn

        • Commission presents a financial support package for Ukraine for 2026-2027 -- EC

        • Global Climate Highlights 2025 -- Copernicus

      • UK:

        • UK borrowing costs fall to lowest in more than a year -- FT

        • Early Data Show UK Economy Struggling in Budget Aftermath -- Bloomberg

        • Government drops plans for mandatory digital ID to work in UK -- BBC

        • New Birmingham to Manchester rail line to be built -- skynews

      • Germany:

        • German economy faces challenges as domestic industry under strains -- Irishnews

      • France:

        • France's Bond Sale to Test Demand as Budget Risks 'Danger Zone' -- Bloomberg

    • Company news:

      • Notable Gainers

        • +17.9% BONEX.SS (BONESUPPORT HOLDING SEK208.40, +32.00) -- prelim. Q4 and FY26 outlook

        • +15.0% CRTA.LN (Cirata £0.24, +0.03) -- FY trading update

        • +12.0% ORNBV.FH (Orion €68.65, +7.55) -- FY26 guidance

        • +8.1% EMSN.SW (EMS-Chemie Holding CHF609.00, +46.00) -- UBS upgrade

        • +7.8% XAR.LN (Xaar £1.09, +0.08) -- FY trading update

        • +7.2% JYSK.DC (Jyske Bank DKK928.50, +63.50) -- raises FY25 guidance

        • +7.0% BAYN.GR (Bayer AG €40.09, +2.73) -- Nubeqa net sales guidance; NICE recommendation of Eidos's Beyonttra to treat wild-type or hereditary transthyretin amyloidosis with cardiomyopathy

        • +6.9% IPN.FP (Ipsen €131.80, +8.80) -- 14 abstract presentations across multiple neurological conditions at the TOXINS 2026 conference; FDA Breakthrough Therapy Designation for IPN60340

        • +6.9% DPP.LN (DP Poland £0.08, +0.01) -- FY trading update

        • +5.2% FEVR.LN (Fevertree Drinks £8.64, +0.44) -- BofA upgrade

        • +4.8% MUL.LN (Mulberry Group £1.13, +0.05) -- Q3 trading update

        • +4.3% KNIN.SW (Kuehne & Nagel CHF188.00, +7.70) -- Goldman Sachs upgrade

        • +4.1% ERA.FP (Eramet €79.00, +3.25) -- Oddo upgrade

        • +3.8% YAR.NO (Yara International NOK415.20, +15.30) -- Deutsche Bank upgrade

        • +3.7% RBREW.DC (Royal Unibrew DKK589.50, +21.00) -- BofA upgrade

        • +3.6% VWS.DC (Vestas Wind Systems DKK187.80, +6.60) -- sympathy with RWE on back of UK Allocation Round 7 (AR7) results

        • +3.3% FDEV.LN (Frontier Developments £5.05, +0.15) -- H1 earnings and FY outlook upgrade

        • +3.0% GLEN.LN (Glencore £4.78, +0.14) -- Rio Tinto reported to have engaged multiple banks to advise on the potential acquisition of Glencore - Reuters

        • +2.7% VCT.FP (Vicat €76.90, +2.00) -- Oddo upgrade

        • +2.5% TELIA.SS (Telia Co. SEK39.53, +0.98) -- Citi upgrade

        • +2.4% AZN.LN (AstraZeneca £142.14, +3.38) -- NICE recommendation of Eidos's Beyonttra to treat wild-type or hereditary transthyretin amyloidosis with cardiomyopathy; Phase III SACHI results published in The Lancet; to acquire Modella AI

        • +2.3% DIE.BB (D'Ieteren Group €171.30, +3.80) -- initiated buy at Berenberg

        • +2.3% RWE.GR (RWE €49.80, +1.11) -- strategic partnership with KKR on UK offshore windfarms

      • Notable Decliners

        • -27.0% NOBI.SS (Nobia SEK4.02, -1.41) -- ~SEK1.5B rights issue; to divest its UK operations to funds managed by Alteri Partners LLP with related prelim. impairment of ~SEK750M

        • -9.6% BNN.GR (BRAIN Biotech €2.48, -0.26) -- prelim. FY earnings

        • -9.5% PSON.LN (Pearson £10.41, -1.03) -- FY trading update

        • -9.0% VTY.LN (Vistry Group £6.35, -0.62) -- FY trading update

        • -7.4% MEGP.LN (ME Group International £1.34, -0.11) -- holder FPCI Montefiore Investment IV sells 12.5M shares at 132p/share

        • -6.0% FME.GR (Fresenius Medical Care €37.25, -2.37) -- remarks from J.P. Morgan Healthcare Conference

        • -5.5% LHA.GR (Deutsche Lufthansa €8.52, -0.48) -- Barclays downgrade

        • -5.1% AF.FP (Air France-KLM €10.90, -0.58) -- Davy downgrade; Barclays downgrade

        • -5.0% HAS.LN (Hays Plc £0.50, -0.03) -- Q2 trading update

        • -4.0% TUB.SM (Tubacex €3.34, -0.15) -- FY25 impairments

        • -3.8% JMT.PL (Jeronimo Martins €20.64, -0.80) -- prelim. Q4 revenue

        • -3.4% FSKRS.FH (Fiskars €12.56, -0.44) -- SEB downgrade

        • -3.2% ORIOLA.FH (Oriola €1.23, -0.04) -- Inderes downgrade

        • -1.5% RLE.LN (Real Estate Investors £0.32, -0.01) -- FY Trading Update

    • EU companies reporting tomorrow:

      • Earnings:

        • UK: Safestore Holdings (SAFE.LN)

      • Trading Updates:

        • Benelux: Fastned (FAST.NA)

        • DACHs: Richemont (CFR.SW), Geberit (GEBN.SW), Bossard Holding (BOSN.SW), Valiant Holding (VATN.SW), OMV (OMV.AV)

        • UK: Taylor Wimpey (TW.LN), Dunelm Group (DNLM.LN), Rathbones Group (RAT.LN), Ashmore Group (ASHM.LN), Brooks MacDonald Group (BRK.LN), Fuller, Smith & Turner (FSTA.LN), CAB Payments Holdings (CABP.LN), Robert Walters (RWA.LN)

        • Other: Pepco Group (PCO.PW), Glenveagh Properties (GVR.ID)

  • Data:

    • Economics:

      • Finland Dec CPI +0.2% y/y vs consensus +0.2% and prior (0.1%)

    • Markets:

      • WTI Crude (26-Feb): +$0.28 or +0.46% to $61.43

      • €-$ +0.0010 or +0.09% to 1.1655

      • £-$ +0.0022 or +0.16% to 1.3445

      • €-£ (0.0006) to 0.8669

      • S&P 500 (0.95%)

      • Performance year-to-date:

        • FTSE 100: +2.55%

        • DAX: +3.25%

        • CAC: +2.23%

        • MIB: +1.56%

        • Stoxx 600: +3.27%

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE